CATL Shares Fall as Hungary Plant Faces Safety Halt 
Dollar Hits Two-Week High as Iran Conflict Lifts Oil and Bond Yields 
Gold Prices Steady as U.S.-Iran Tensions Lift Inflation Risks 
Dollar Holds Near Two-Week High as Fed Rate Hike Bets Rise 
CIA-Linked Investor Helped Quantum Systems Expand in US 
Shein Shares Slide 9% in Hong Kong IPO Debut 
Asian Tech Stocks Slide as Fed Rate Hike Bets Rise 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
Australia GDP Beats Forecast, Boosting RBA Rate Hike Bets 
German Retail Sales Drop 3.4% in July 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Star Entertainment Shares Fall After A$307 Million FY2026 Loss 
Ukraine Sanctions Chief Heads to Washington to Push Russia Bill 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
Add as a preferred source on Google
Moderna has assigned its new chief medical officer after recruiting a former Johnson & Johnson executive. It was reported that effective on July 6, Dr. Paul Burton will be joining the American pharmaceutical and biotechnology company based in Cambridge, Massachusetts.
As per Market Watch, Dr. Burton worked in Janssen Pharmaceuticals as its chief global medical affairs officer from March 2020, but he has been with Johnson & Johnson for 16 years and held various executive positions during his tenure.
Burton moves to Moderna
Dr. Paul Burton will be replacing Tal Zaks, who is said to be leaving Moderna after six years with the company. The incoming Moderna medical chief was also said to have previously worked as the vice president and head of cardiovascular and metabolic medical affairs in J&J.
He will be joining the biotech firm at the time when it is seeking approval from the government’s health regulators so that its COVID-19 vaccine could be used for adolescents too. Moderna’s chief executive officer, Stephane Bancel, said that testing results for the use of the vaccine in children will be available by fall. If the outcome is good, she said that it could help get a nod from the regulators and health safety boards.
“Paul’s extensive medical experience in the global pharmaceutical and biotech industry will be important to Moderna as we expand internationally and continue our journey as a commercial company,” CEO Bancel said in a press release. “As we work to deliver on the promise of mRNA science to create a new generation of transformative medicines for patients, Paul’s expertise across multiple therapeutic areas and his proven track record leveraging data science and digital technologies to reimagine medical engagement will be invaluable.”
Moderna’s foray into COVID-19 vaccine production
Moderna’s name became popular after joining the list of pharmaceutical firms that develop and produce vaccines for COVID-19. Its label was often in the headlines since last year, and now it is considered as one of the leading suppliers of vaccines worldwide.
Moderna’s CEO believes that with Dr. Paul Burton’s expertise, the company will achieve more of its goals in the coming years. She said that she is really looking forward to working with the new medical chief as they could achieve many things together.
